4th Quarter - Amendment

DAVITA INC. for DAVITA INC

Firm
Client
Income
—
Expenses
$1,100,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 19, 2021 $1,080,000 Replaced
4th Quarter - Amendment (this page) Apr 19, 2021 $1,100,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Veterans VET

Issues related to Veterans Affairs and dialysis Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021, provisions related to dialysis (no bill number) H.R. 133, Consolidated Appropriations Act, 2021, dialysis and kidney care issues

LobbyistCovered position, as disclosed
JAVIER DEJESUS BARAJAS MARTINEZ —
KELLY PHILSON —
JOELLE OISHI THORNHILL —
LEANNE M ZUMWALT —

Contacted: Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 133 (116th)

Health Issues HCR

H.R. 8254/S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912/S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Emergency response related to COVID-19 H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133, Consolidated Appropriations Act, 2021, dialysis and kidney care issues

LobbyistCovered position, as disclosed
JAVIER DEJESUS BARAJAS MARTINEZ —
KELLY PHILSON —
JOELLE OISHI THORNHILL —
LEANNE M ZUMWALT —

Contacted: Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5534 (116th), H.R. 8254 (116th), S. 4574 (116th), S. 3353 (116th), H.R. 133 (116th), H.R. 3912 (116th), S. 1676 (116th)

Medicare/Medicaid MMM

H.R. 8254/S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Emergency response related to COVID-19 H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133, Consolidated Appropriations Act, 2021, dialysis and kidney care issues

LobbyistCovered position, as disclosed
JAVIER DEJESUS BARAJAS MARTINEZ —
KELLY PHILSON —
JOELLE OISHI THORNHILL —
LEANNE M ZUMWALT —

Contacted: HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 133 (116th), S. 3353 (116th), H.R. 3912 (116th), H.R. 8254 (116th), S. 1676 (116th), S. 4574 (116th), H.R. 5534 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.